Diabetes Mellitus Type 1
Conditions
Brief summary
A keystone in preventing diabetic complications in patients with type 1 diabetes is good glycaemic control. Frequent self-measurements of blood glucose (SMBG) levels have been an essential part of insulin dosing before meals. However, in recent years continuous glucose monitoring (CGM) has become a treatment option to inform the patient when glucose levels may be too high or low. In some countries, including Sweden, CGM is reimbursed only when combined with continuous subcutaneous insulin infusions (CSII) in patients with very poor glycaemic control or a history of repeated severe hypoglycaemia in adults with type 1 diabetes. This is based on existing clinical trial data showing a beneficial effect on HbA1c when CGM is combined with CSII. However, despite the fact that the majority of adults with type 1 diabetes are treated with multiple daily insulin injections (MDI), studies on the effect of CGM in patients with type 1 diabetes treated with MDI are sparse. Therefore, the investigators initiated the CGMMDI trial, an ongoing, cross-over clinical trial including 161 MDI patients receiving CGM over 6 months, followed by conventional therapy over six months, with a four-month wash-out period in-between treatment. Evaluations include glycaemic control, hypoglycaemia, quality of life, fear of hypoglycaemia, treatment satisfaction, physical activity, and safety. From a research or regulatory standpoint, long-term data on treatment effects are expected to a greater extent today than in previous years, due to various reasons, e.g., to evaluate any sustained beneficial effects over time, or long-term patient safety. Accordingly, follow-up of treatment in an extension phase after randomized diabetes trials have become more common over time, especially where many novel glucose-lowering treatments are concerned. Therefore, the aim of the current study is to evaluate long-term effects of CGM in patients with type 1 diabetes treated with MDI. Patients who consent in an extension phase over 1 year of the CGMMDI trial will receive CGM, and evaluations will be performed on sustained glycaemic control effects, hypoglycaemia, glycaemic variability, quality of life, fear of hypoglycaemia, treatment satisfaction, physical activity, and safety.
Interventions
DEVICEDexcom G4 or later generation
Continuous glucose monitoring with DexCom G4 platina or later generations
Sponsors
DexCom, Inc.
Vastra Gotaland Region
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Completion of the CGMMDI trial. * Written informed consent.
Exclusion criteria
* Pregnancy, planned pregnancy for the study duration or pregnancy during the last six months * Severe cognitive dysfunction or other disease, which is adjudicated by a physician as not suitable for inclusion. * Required continuous use of paracetamol. Paracetamol must not have been used the week before the study and shall not be used during CGM-use because it disturbs the interpretation of blood glucose levels estimated by the Dexcom. However, other pain killers can be used throughout the study duration. * History of allergic reaction to any of the CGM materials or adhesives in contact with the skin, or to chlorhexidine or alcoholic anti-septic solution. * Abnormal skin at the anticipated glucose sensor attachment sites (excessive hair, burn, inflammation, infection, rash, and/or tattoo). * Other investigator-determined criteria making patients unsuitable for participation.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| HbA1c in venous sample | 52 weeks or 78 weeks | For all variables, measurement at the end of this extension of a cross-over study will be compared to the measurement before long-term CGM was initiated. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of patients lowering their HbA1c by 5 mmol/mol (0.5% in DCCT) or more. | 52 weeks/78 weeks | — |
| Mean glucose level measured by CGM during two weeks. | 52 weeks/78 weeks | — |
| Mean Amplitude of Glycemic Excursions (MAGE) measured by CGM during two weeks. | 52 weeks/78 weeks | — |
| Standard deviation of glucose levels measured by CGM during two weeks. | 52 weeks/78 weeks | — |
| Treatment satisfaction: DTSQs scores | 52 weeks/78 weeks | Diabetes Treatment Satisfaction Questionnaire (Status) |
| Well being: WHO 5 scores | 52 weeks/78 weeks | Questionnaire |
| Hypoglycemia fear: SWE-HFS scores | 52 weeks/78 weeks | Swedish Hypoglycaemia Fear Scale Questionnaire |
| Proportion of time with euglycaemic levels measured by CGM during two weeks. | 52 weeks/78 weeks | 5.5-10.0 mmol/l and 3.9-10.0 mmol/l, respectively. |
| Physical activity: IPAQ score | 52 weeks/78 weeks | International Physical Activity Questionnaire |
| Treatment experience of CGM score | 52 weeks/78 weeks | Questionnaire developed for this trial |
| Proportion of time with low glucose levels measured by CGM during two weeks. | 52 weeks/78 weeks | Below 3.0 mmol/l and below 4.0 mmol/l, respectively. |
| Proportion of time with high glucose levels measured by CGM during two weeks. | 52 weeks/78 weeks | Above 10.0 mmol/l and above 13.9 mmol/l, respectively. |
| Proportion of patients lowering their HbA1c 10 mmol/mol (1% in DCCT) or more | 52 weeks/78 weeks | — |
| Number of self-reported severe hypoglycaemic events per year | 52 weeks/78 weeks | Defined as unconsciousness due to hypoglycaemia or need for assistance from another person to resolve hypoglycaemia. |
| Problem areas: SWE-PAID-20 scores | 52 weeks/78 weeks | Swedish Problem Areas In Diabetes Questionnaire |
Countries
Sweden
Outcome results
None listed